Kyowa Kirin to acquire Orchard Therapeutics in deal worth $477m
The deal gives Kyowa access to a therapy for early-onset metachromatic leukodystrophy
Read More
Tag: Libmeldy
NICE ‘no’ for Orchard Therapeutics’ gene therapy Libmeldy
NICE concluded the cost-effectiveness estimates for Libmeldy are unlikely to be within the range that it would consider an effective use of NHS resources
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
